To evaluate the efficacy and safety of ZED1227, a selective TG2 inhibitor, in preventing gluten-induced intestinal mucosal damage and improving symptoms in celiac disease patients undergoing a controlled gluten challenge. Here, TGM2 is linked to celiac disease.